Ayala Pharmaceuticals (AYLA) – Buying Opportunity With Clinical Trial Milestones Ahead

Tuesday, March 15, 2022

Ayala Pharmaceuticals (AYLA)
Buying Opportunity With Clinical Trial Milestones Ahead

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Ayala Is Developing Drugs To Block Activation Of The Notch Pathway.  Under normal conditions, the Notch pathway provides signals that regulate cell growth and maintenance. Mutations in the Notch pathway can lead to loss of regulation and proliferation of cancerous cells. Ayala has developed drugs that block gamma secretase, an enzyme that activates the Notch pathway.

    AL102 and AL102 Act By Inhibiting An Activation Step In The Notch Pathway.  Ayala has developed AL101 and AL102, two drugs that block gamma secretase, an enzyme needed to activate the Notch pathway. This stops the signaling steps that lead to overactivity and proliferation of cancer cells …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights



Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Research, News, and Market Data on Tonix Pharmaceuticals

 

Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headache and Binge Eating Disorder

Covid-19 Programs Include Upcoming Phase 2 Trial in Long Covid, Results of First-in-Human T Cell Immunity Skin Test and New Versions of Our Live Virus Covid-19 Vaccine That Express Spike Proteins From the Omicron and BA.2 Variants

Expansion of Internal Research and Development Capabilities Underway to Accelerate Infectious Disease Programs and Prepare for Future Pandemic Responses

Orphan-Drug Designation Granted for TNX-2900 (Intranasal Potentiated Oxytocin) for Prader-Willi Syndrome

Cash and Cash Equivalents Totaled Approximately $179 Million at December 31, 2021

CHATHAM, N.J., March 14, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an overview of recent operational highlights.

“2021 was an important year for Tonix as we delivered on several important milestones to advance our rich pipeline of immunology, central nervous system (CNS) and infectious disease product candidates,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “Our diversified pipeline was built through internal research and development, business development and strategic collaborations. Already in 2022, we have shared results of animal studies of monoclonal antibody TNX-1500 in organ transplantation and announced FDA’s award of Orphan-Drug designation for TNX-2900 for Prader Willi syndrome. We look forward to pharmacogenomic analyses, in conjunction with topline data, for the Phase 3 RALLY study of TNX-102 SL in fibromyalgia in the first quarter of 2022.”

Dr. Lederman continued, “Through acquisitions and the continued buildout of in-house R&D capabilities, Tonix is strengthening its capabilities to develop a broad infectious disease portfolio of product candidates, led by TNX-801 which is a live virus vaccine for smallpox and monkeypox, that is based on horsepox, which is our recombinant pox virus platform (RPV). Also based on the RPV are next-generation vaccine candidates to prevent Covid-19, including TNX-1840 and TNX-1850 which are live virus vaccines designed to express the omicron and BA.2 variants of the spike protein. We look forward to starting a Phase 2 study of TNX-102 SL for Long Covid and reporting topline data from the ongoing first-in-human study of TNX-2100, a diagnostic skin test for T cell immunity to SARS-CoV-2, in the first half of 2022.”

Gregory Sullivan, M.D., Chief Medical Officer of Tonix said, “In 2022, we expect to initiate several clinical trials. We intend to start a Phase 1 study of TNX-1500, a humanized monoclonal antibody with several potential indications including the prevention of organ transplant rejection and treatment of autoimmune disorders. Within our CNS pipeline, we expect to start a Phase 2 study of FDA Breakthrough Therapy-designated product candidate TNX-1300 (recombinant cocaine esterase) for cocaine intoxication in the emergency room setting. We also expect to start three trials for TNX-102 SL (sublingual cyclobenzaprine) including: a confirmatory Phase 3 study for the management of fibromyalgia, a Phase 2 study for the treatment of PTSD, and a Phase 2 study for the treatment of Long Covid. Finally, in 2022 we intend to start a Phase 2 study of TNX-1900 for the treatment of migraine and an investigator-initiated Phase 2 study of TNX-1900 for binge eating disorder.”

Recent Highlights—Key Product Candidates*

Immunology Pipeline

TNX-1500 (anti-CD40L monoclonal antibody): third generation monoclonal antibody for prophylaxis of organ transplant rejection and treating autoimmune disorders.

  • Tonix expects to start a Phase 1 study in the second half of 2022. Preliminary results from ongoing experiments in heart and kidney transplants in non-human primates at Massachusetts General Hospital indicate that TNX-1500 appears to have monotherapy efficacy in promoting rejection-free transplant organ acceptance and no evidence of thrombosis has been observed.

TNX-1700 (stabilized recombinant trefoil factor 2, or rTFF2): biologic for gastric and colorectal cancers

  • In December 2021, Tonix announced a research collaboration with Columbia University focused on advancing TNX-1700 in the treatment of gastric and colorectal cancers. Tonix optioned worldwide rights to develop and commercialize products related to Columbia’s rTFF2 technology, and key patent claims have recently been issued in the U.S. The new project, “Development of rTFF2-Based Therapy to Enhance Immuno-Oncology Treatments,” is the first sponsored research project of this collaboration. The agreement with Columbia University gives Tonix the option to exclusively license new therapeutic candidates and other technologies that arise from the research collaboration for further development. TNX-1700 is in the preclinical stage of development.

Central Nervous System (CNS) Pipeline

TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication

  • Tonix expects to initiate a Phase 2 open-label safety study of TNX-1300 in an emergency room setting in the first half of 2022. TNX-1300 was licensed from Columbia University and a positive Phase 2a study of volunteer cocaine users in a controlled laboratory setting has been completed. TNX-1300 has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

TNX-102 SL (cyclobenzaprine HCl sublingual tablets): small molecule for the management of fibromyalgia (FM)

  • Tonix expects to report topline data from its second Phase 3 study, RALLY, in the first quarter of 2022. Tonix reported interim analysis of RALLY in July 2021 in which the independent data monitoring committee recommended stopping the study for futility. The Company therefore stopped enrollment of new participants while continuing those participating at that time to completion. Tonix plans to employ pharmacogenomic (PGx) techniques to compare the RALLY and RELIEF study populations, which may provide a path to precision medicine-based companion diagnostics for TNX-102 SL in FM.

  • Tonix expects to initiate a new Phase 3 study of TNX-102 SL in FM in the first half of 2022. The Company will use the results of RALLY, including the PGx data, to potentially improve the design of this study.

  • Tonix reported positive results from the Phase 3 RELIEF study for the management of fibromyalgia in December 2020.

TNX-102 SL for the treatment of Posttraumatic Stress Disorder (PTSD)

  • Tonix has completed a meeting with the FDA to discuss potential new endpoints for the treatment of PTSD and expects to begin enrolling a Phase 2 study of TNX-102 SL in police in Kenya in the first half of 2022. The new PTSD study will use one month look-back CAPS-5 as the primary endpoint rather than one week look-back.

TNX-102 SL for the treatment of Long Covid, also known as Post-Acute Sequelae of COVID-19 (PASC)

  • The Company intends to initiate a Phase 2 study in patients with Long Covid in the first half of 2022, pending clearance of an Investigational New Drug (IND) application. The Phase 2 study will focus on a subset of Long Covid patients whose symptoms overlap with those of fibromyalgia.

TNX-1900 (intranasal potentiated oxytocin): small peptide for migraine, craniofacial pain, insulin resistance and related disorders, and binge eating disorder

  • In November 2021, Tonix announced it received IND clearance from the FDA to support the initiation of a Phase 2 study of TNX-1900 for the prevention of migraine headache in chronic migraineurs. The 505(b)(2) pathway for FDA approval is expected to be acceptable for this program, which is available to new formulations of an approved drug. The Company expects to begin enrollment in the second half of 2022.

  • In March 2022, Tonix announced an agreement with Massachusetts General Hospital to evaluate TNX-1900 in an investigator-initiated Phase 2 clinical trial as a potential treatment for patients with binge eating disorder. The Phase 2 clinical trial is expected to start in the second half of 2022.

  • Tonix’s potentiated formulation includes magnesium (Mg), which has been reported to potentiate the binding of oxytocin to the oxytocin receptor. Further evidence for the role of Mg in potentiating the effects of oxytocin at the oxytocin receptor were published by a third party1.

TNX-2900 (intranasal potentiated oxytocin): small peptide for the treatment of Prader-Willi syndrome (PWS)

  • In March 2022, the FDA granted the Company Orphan-Drug designation for TNX-2900 for the treatment of PWS.
  • In February 2022, Tonix entered into a sponsored research agreement with Inserm (the French National Institute of Health and Medical Research) and Aix-Marseille Université to study oxytocin in the genetically engineered mouse model of Prader-Willi syndrome, a rare genetic disorder that causes distinct, but related pathological eating disorders in adults and newborns. In adults, PWS causes hyperphagia, or pathological over-eating, which leads to obesity and other complications associated with significant mortality. In newborns, PWS causes a deficiency in suckling, which can lead to low muscle tone and failure to thrive, and has been shown to be normalized by oxytocin treatment.

TNX-601 CR (tianeptine oxalate and naloxone controlled-release tablets): small molecule for the treatment of major depressive disorder, PTSD and neurocognitive dysfunction associated with corticosteroid use.

  • Based on official minutes from a pre-IND meeting with the FDA, the Company expects to initiate a Phase 2 study for the treatment of major depressive disorder (depression) in the first quarter of 2023. Tonix plans to initiate a pharmacokinetic study in the third quarter of 2022. Tonix previously completed a Phase 1 trial for formulation development outside of the U.S.

Infectious Disease Pipeline

TNX-801 (live horsepox virus vaccine for percutaneous administration): smallpox and monkeypox vaccine designed as a single-administration vaccine to elicit T cell immunity

  • Tonix previously reported protection of non-human primates from a monkeypox challenge2. TNX-801 is less virulent than traditional vaccinia vaccines in mice.3

TNX-1840 /-1850 (live virus vaccines based on Tonix’s recombinant pox virus vector): COVID-19 vaccines designed as a single-administration vaccine to elicit T cell immunity

  • Because the omicron variant has out-competed the ancestral Wuhan strain, Tonix is now planning new versions of the TNX-1800 vaccine: TNX-1840 and TNX-1850, that are designed to express spike protein from the omicron and BA.2 variants, respectively. TNX-1840 and TNX-1850 are next-generation COVID-19 vaccines using live virus technology, which is known to primarily elicit a T cell response believed to result in longer durability and the blocking of forward transmission.

TNX-3500 (sangivamycin): antiviral inhibitor of SARS-CoV-2 for the treatment of COVID-19 and potential other viral disorders

  • In November 2021, Tonix announced the publication of “Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties,” in JCI Insight. The paper includes in vitro studies conducted by the National Institutes of Allergy and Infectious Diseases that show sangivamycin, the active pharmaceutical ingredient in TNX-3500, is a potent antiviral against SARS-CoV-2, the cause of COVID-19, and suppresses viral replication in tissue culture with greater potency than remdesivir, the active pharmaceutical ingredient of Gilead Sciences, Inc.’s Veklury®. When tested in combination with remdesivir, both drugs had additive rather than competitive effect against SARS-CoV-2.

  • Tonix plans to conduct further nonclinical animal studies of TNX-3500.

TNX-3600: COVID-19 therapeutic; fully human monoclonal antibody platform

  • In September 2021, Tonix expanded its research collaboration with Columbia University focused on studying immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic, as well as studying in vitro T cell and antibody responses to SARS-CoV-2, the virus that causes COVID-19. The research is designed to fill in important gaps in comprehensive understanding of immune responses to COVID-19, and to provide a foundation for tailoring vaccines and therapeutics to appropriate individuals with precision medicine. Specifically, the researchers will study T cell and antibody responses in a variety of ways, including at the cellular level by stimulating T cells in vitro with CoV-2 antigens and by generating fully human monoclonal antibodies against SARS-CoV-2. Tonix believes that this research has the potential to lead to the isolation, characterization and cloning of therapeutically relevant fully human neutralizing monoclonal antibodies to SARS-CoV-2.

TNX-3700: COVID-19 mRNA vaccine candidate using a zinc nanoparticle (ZNP) formulation

  • In January 2022, Tonix announced an exclusive option and research collaboration with Kansas State University (K-State) to develop ZNP mRNA vaccines that replace the lipid nanoparticle (LNP) technology in current COVID-19 vaccines. The new ZNP technology has the potential to confer increased stability to mRNA vaccines over a wide range of temperatures, addressing limits to rapid global deployment. Under the research agreement, K-State will advance preclinical development of a new ZNP mRNA vaccine to protect against COVID-19 based on the spike protein from SARS-CoV-2.

TNX-2100 (diagnostic skin test): SARS-CoV-2 epitope peptide mixtures for intradermal administration to measure the delayed-type hypersensitivity (DTH) reaction to SARS-CoV-2

  • Tonix initiated enrollment in a first-in-human, dose-finding clinical study for TNX-2100, which is designed to measure functional in vivo T cell immunity to SARS-CoV-2, with results expected in the first half of 2022.
  • TNX-2100 comprises three different mixtures of synthetic peptides (TNX-2110, -2120 and -2130), which has the potential to serve as: 1) a biomarker for T cell protective immunity and durability of vaccine protection; 2) a personalized approach for vaccine boosters; 3) a method to stratify participants in COVID-19 vaccine trials with a more complete picture of immune status; 4) an endpoint in COVID-19 vaccine trials for vaccines that elicit T cell immunity, and 5) public health surveillance.

*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.

2021 Highlights—Facilities and Corporate

  • In December 2021, Tonix was added to the Nasdaq Biotechnology Index as part of Nasdaq’s annual reconstitution process.

  • In June 2021, Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

  • R&D Center (RDC): In October 2021, Tonix completed the acquisition of its 48,000 square foot research and development center (RDC) in Frederick, Md. The facility is operational and will focus on the development of vaccines and antiviral drugs against COVID-19, its variants, and other infectious diseases. The RDC facility is currently biosafety level 2 (BSL-2), but Tonix plans to make appropriate upgrades and seek certification for BSL-3 so that research may be conducted on live SARS-CoV-2 and other pathogens.

  • Advanced Development Center (ADC): In August 2021, Tonix commenced construction on the ADC for the development and manufacturing of Good Manufacturing Practice, or GMP, live-virus vaccines to support Phase 1 and 2 clinical trials. The facility, located in the New Bedford Business Park in Dartmouth, Mass., is planned to be BSL-2 and expected to be partially operational in the first half of 2022.

  • Commercial Manufacturing Center (CMC): Tonix plans to build the CMC in Hamilton, Mont. where it purchased approximately 44 acres of land. The CMC will focus on developing and manufacturing commercial scale live-virus vaccines and is also intended to be BSL-2. Site enabling work is expected to be initiated for the CMC in 2022.

1Meyerowitz, J.G., Robertson, M.J., Barros-Álvarez, X. et al. The oxytocin signaling complex reveals a molecular switch for cation dependence. Nat Struct Mol Biol (2022). https://doi.org/10.1038/s41594-022-00728-4
2Noyce, RS, et al. Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Presented as a poster at the American Society of Microbiology BioThreats Conference – January 29, 2020, Arlington, VA. (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf )
3Noyce RS, et al. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS One. 2018 Jan 19;13(1): e0188453.

Recent Highlights–Financial

As of December 30, 2021, Tonix had $178.7 million of cash and cash equivalents, compared to $77.1 million as of December 31, 2020. Subsequent to December 31, 2021, the Company sold 15.6 million shares of common stock in at-the-market offerings (ATM) sales under a Sales Agreement with A.G.P./Alliance Global Partners, for net proceeds of approximately $4.3 million. Additionally, the Company sold 22.0 million shares of common stock under the Purchase Agreement with Lincoln Park for net proceeds of approximately $4.5 million.

Cash used in operations was approximately $75.6 million for the full year ended December 31, 2021, compared to $48.6 million for the full year ended December 31, 2020. The increase in primarily due to an increase in research and development (R&D) and general and administrative (G&A) activities, described below.

Fourth Quarter 2021 Financial Results

R&D expenses for the fourth quarter of 2021 were $22.3 million, compared to $12.1 million for the same period in 2020. This increase is predominately due to increased clinical expenses of $1.9 million, increased manufacturing expenses of $2.1 million, non-clinical expenses of $2.4 million, employee-related expenses of $2.3 million and regulatory/legal expenses of $0.6 million. We expect R&D expenses to increase during 2022 as we move our clinical development programs forward and continue to invest in our development pipeline.

G&A expenses for the fourth quarter of 2021 were $7.3 million, compared to $4.9 million for the same period in 2020. The increase is primarily due to employee-related expenses of $1.8 million.

Net loss available to common stockholders was $29.6 million, or $0.07 per share, basic and diluted, for the fourth quarter of 2021, compared to net loss of $17.0 million, or $0.10 per share, basic and diluted, for the fourth quarter of 2020. The basic and diluted weighted average common shares outstanding for the fourth quarter of 2021 was 451,209,777, compared to 163,873,489 shares for the fourth quarter of 2020.

Full Year 2021 Financial Results

R&D expenses for full year 2021 were $68.8 million, compared to $36.2 million for the same period in 2020. This increase is predominately due to increased non-clinical expenses of $14.0 million, manufacturing expenses of $10.9 million, employee-related expenses of $5.3 million and regulatory/legal expenses of $1.9 million. We expect R&D expenses to increase during 2022 as we move our clinical development programs forward and continue to invest in our development pipeline.

G&A expenses for full year 2021 were $23.5 million, compared to $14.4 million for the same period in 2020. The increase is primarily due to employee-related expenses of $4.9 million, an increase in legal fees of $0.7 million due to increased patent prosecution costs, an increase in investor relations/public relations expenses of $0.6 million, an increase in financial reporting expenses of $1.2 million, and an increase in insurance premiums of $0.4 million.

Net loss available to common stockholders was $92.3 million, or $0.26 per share, basic and diluted, for full year 2021, compared to net loss of $52.2 million, or $0.55 per share, basic and diluted, for full year 2020. The basic and diluted weighted average common shares outstanding for full year 2021 was 360,215,323, compared to 94,591,715 shares for full year 2020.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, central nervous system (CNS) and infectious disease product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including Tonix’s lead immunology candidate, TNX-15001, is a humanized monoclonal antibody targeting CD40 ligand being developed for the prevention of allograft rejection and the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to start in the second half of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL2, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug in mid-Phase 3 development for the management of fibromyalgia, with a new Phase 3 study expected to start in the first half of 2022. TNX-102 SL is also being developed to treat Long COVID, a chronic post-COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022. TNX-13003 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the first half of 2022. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox, next-generation vaccines to prevent COVID-19 and an antiviral to treat COVID-19. Tonix’s lead vaccine program is TNX-801 (live horsepox virus for percutaneous administration) for preventing smallpox and monkeypox4. Horsepox is also the basis for Tonix’s recombinant pox vaccine (RPV) platform. Tonix’s lead vaccine candidates for COVID-19, TNX-1840 and TNX-18505, are live virus vaccines in development based on the RPV platform. Finally, TNX-35006 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

2TNX-102 SL is an investigational new drug and has not been approved for any indication.

3TNX-1300 is an investigational new biologic and has not been approved for any indication.

4TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

5TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. TNX-1840 and TNX-1850 are designed to express the spike protein of SARS-CoV-2 from omicron and BA.2 variants, respectively, based on the experience from TNX-1800, which expresses the spike protein from the ancestral Wuhan strain.

6TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K and periodic reports filed with the SEC. All Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

TONIX PHARMACEUTICALS HOLDING CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, In Thousands, Except Share and Per Share Amounts)

      Full Year Ended       Three Months Ended   
      December 31,         December 31,    
      2021       2020       2021       2020  
Costs and expenses                                
Research and development   $ 68,838     $ 36,157     $ 22,296     $ 12,097  
General and administrative     23,474       14,354       7,264       4,926  
Total costs and expenses     92,312       50,511       29,560       17,023  
Operating loss     (92,312 )     (50,511 )     (29,560 )     (17,023 )
Interest income, net     25       48       7       2  
Net loss   $ (92,287 )   $ (50,463 )   $ (29,553 )   $ (17,021 )
Warrant deemed dividend           (451 )            
Preferred stock deemed dividend           (1,260 )            
Net loss available to common stockholders   $ (92,287 )   $ (52,174 )   $ (29,553 )   $ (17,021 )
Net loss per common share, basic and diluted   $ (0.26 )   $ (0.55 )   $ (0.07 )   $ (0.10 )
Weighted average common shares outstanding, basic and diluted     360,215,323       94,591,715       451,209,777       163,873,489  


     

TONIX PHARMACEUTICALS HOLDING CORP.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2021 AND 2020
(In Thousands)

  December 31, 20211
  December 31, 20201
Assets    
Cash and cash equivalents $ 178,660   $ 77,068
Prepaid expenses and other   10,389     10,921
Total current assets   189,049     87,989
Other non-current assets   51 ,851     10,194
Total assets $ 240,900   $ 98,183
     
Liabilities and stockholders’ equity    
Total liabilities $ 22,183   $ 10,535
Stockholders’ equity   218,717     87,648
Total liabilities and stockholders’ equity $ 240,900   $ 98,183

The condensed consolidated balance sheets for the years ended December 31, 2021 and December 31, 2020 have been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

Genetically Modifying Pigs Organs Could offset Transplant Demand



Image Credit: University of Maryland School of Medicine


Organs from Genetically Engineered Pigs May Help Shorten the Transplant Wait List

 

Demand for life-saving organ transplantation is at an all-time high. In 2021, a record 41,000-plus organ transplants were performed in the U.S., with top numbers for kidney, liver and heart transplants. But a limited supply of donor organs remains an ongoing problem. Currently, over 100,000 people are on the transplant wait list in the U.S., and many more are unable to get on the list because of strict eligibility requirements and racial disparities in access.

 

This article was republished with permission from   The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of David Kaczorowski Associate Professor of Cardiothoracic Surgery, University of Pittsburgh Health Sciences.

 

As a cardiac transplant surgeon, I have personally witnessed the tragedy of this shortage of donor organs. But I have also seen the potential of one possible solution to this problem: xenotransplantation, or transplanting animal organs into human beings.

In September 2021, researchers successfully transplanted two genetically engineered pig kidneys into a brain-dead patient. And in January 2022, I was part of the surgical team that conducted the first pig-to-human heart transplant in a living patient. Recent news about the patient’s death two months after the procedure is sobering, but researchers like me remain optimistic. While much work still needs to be done, these successes point to how far science has come toward making animal-to-human transplants a viable treatment possibility.

The man who received the first pig heart transplant died on March 8, 2022, two months after the procedure.

Early Attempts

While animal-to-human transplants have attracted considerable attention recently, many attempts have been made to transplant animal cells, tissues and organs into humans over the past 60 years, with varying degrees of success.

In the 1960s, kidney transplantation was not broadly practiced because of a lack of donor organs. Ethical and legal concerns made it difficult to obtain live donors, and organs collected from deceased donors did not meet much success.

A surgeon named Keith Reemtsma performed a series of 12 kidney transplants using chimpanzees as donors. While most of the transplanted organs – and thus the human patients – survived for only a few weeks, one of the patients survived for nine months. Infection was the major issue in half of the patients, while irreversible organ rejection occurred in the other half.

Thomas Starzl is another surgeon who attempted animal-to-human organ transplants. He performed a similar series of kidney transplants around the same time as Reemtsma using baboons as donors, with the organs surviving up to two months. He’s most known for his liver transplants, with three attempts using chimpanzee livers from 1966 to 1974 that lasted from 24 hours to less than 14 days. In the early 1990s, his two baboon liver transplants lasted for 26 and 70 days. While one of the baboon livers functioned well, the patient ultimately died from overwhelming infection.

 

Image: Baby Fae was the first successful infant xenotransplant, surviving for 20 days with a baboon heart.

 

Doctors have also made attempts to transplant animal hearts, the first of which predated the first human-to-human heart transplant. In 1964, a chimpanzee heart transplanted by James Hardy survived for only a few hours. Len Bailey’s 1983 attempt at transplanting a baboon heart into an infant known as Baby Fae prolonged her life for 20 days, a record at the time.

 

Overcoming Barriers

While these early results may seem poor at first glance, a number of these transplants actually lasted longer than many early human-to-human kidney transplants. The first patient to receive a donated kidney lasted for only four days in 1933, and later attempts in the 1940s and 1950s yielded similar results. Immunosuppressing drugs that prevent the immune system from attacking donor organs also weren’t available at the time of these early attempts at xenotransplantation, pointing to the promise of these procedures as science advanced.

But transplanting organs across species faces a number of obstacles, the most integral of which is evolution. As species grow apart, increasing differences in their molecular makeup can result in incompatibilities that make cross-species transplants difficult or impossible. Among the most problematic are differences in immunity, inflammation and blood clotting that damage both the transplanted organs and the host’s body.

The similarity of nonhuman primates like chimpanzees and baboons to humans, both in anatomy and in their immune systems, made them appealing donors for early transplants. But their strong similarities to people also raised ethical concerns that dissuaded some physicians like Starzl from using them as donors.

On the other hand, pigs offer a potentially better source of donor organs. Compared with nonhuman primates, pigs mature much more quickly and produce more offspring. They are also a common source of food for people, and their tissues are already used for prosthetic heart valves and other medical treatments.

While pig-to-human transplants have also been attempted in the past, 80 million years of evolution stood in the way. Pigs have molecules on the surfaces of their cells that humans do not. If these molecules are introduced into a person’s body, their human immune system will register them as foreign and mount an attack. This process, called hyperacute rejection, is a central reason many transplanted animal organs fail.

A number of advances that reduce these incompatibilities have helped overcome the problem of hyperacute rejection. Genetically engineered pigs without the genes that produce the foreign molecules triggering rejection and with additional human genes that help the recipient’s body accept the new organ are one key improvement. The pig heart my team and I transplanted this year was genetically engineered, as were the pig kidneys from late 2021. There have also been improvements in medications that suppress the immune system of the recipient so it’s less likely to mount an attack against the organ.

 

Looking Forward

Recent successes with genetically engineered pig transplants make clear that xenotransplantation is no longer a dream from a distant future but something becoming increasingly achievable by modern medicine.

But many questions still remain. What is the best way to suppress a recipient’s immune system so the transplanted organ survives but the risk of infection stays low? Can animal organs be tailored to individuals to minimize rejection? How can animal organs be better preserved and distributed?

Answering these and many other questions will be key to realizing the therapeutic potential of xenotransplantation, and helping the hundreds of thousands of people waiting for an organ.

 

Suggested Content



Longeveron at World Stem Cell Summit (Video)



Cocrystal Pharma, Virtual Road Show (Video)





Baudax Bio, C-Suite Interview (Video)



Type 1 Diabetes, The Beginning of the End (Video)

 

Stay up to date. Follow us:

 

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights



Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Research, News, and Market Data on Tonix Pharmaceuticals

 

Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headache and Binge Eating Disorder

Covid-19 Programs Include Upcoming Phase 2 Trial in Long Covid, Results of First-in-Human T Cell Immunity Skin Test and New Versions of Our Live Virus Covid-19 Vaccine That Express Spike Proteins From the Omicron and BA.2 Variants

Expansion of Internal Research and Development Capabilities Underway to Accelerate Infectious Disease Programs and Prepare for Future Pandemic Responses

Orphan-Drug Designation Granted for TNX-2900 (Intranasal Potentiated Oxytocin) for Prader-Willi Syndrome

Cash and Cash Equivalents Totaled Approximately $179 Million at December 31, 2021

CHATHAM, N.J., March 14, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided an overview of recent operational highlights.

“2021 was an important year for Tonix as we delivered on several important milestones to advance our rich pipeline of immunology, central nervous system (CNS) and infectious disease product candidates,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “Our diversified pipeline was built through internal research and development, business development and strategic collaborations. Already in 2022, we have shared results of animal studies of monoclonal antibody TNX-1500 in organ transplantation and announced FDA’s award of Orphan-Drug designation for TNX-2900 for Prader Willi syndrome. We look forward to pharmacogenomic analyses, in conjunction with topline data, for the Phase 3 RALLY study of TNX-102 SL in fibromyalgia in the first quarter of 2022.”

Dr. Lederman continued, “Through acquisitions and the continued buildout of in-house R&D capabilities, Tonix is strengthening its capabilities to develop a broad infectious disease portfolio of product candidates, led by TNX-801 which is a live virus vaccine for smallpox and monkeypox, that is based on horsepox, which is our recombinant pox virus platform (RPV). Also based on the RPV are next-generation vaccine candidates to prevent Covid-19, including TNX-1840 and TNX-1850 which are live virus vaccines designed to express the omicron and BA.2 variants of the spike protein. We look forward to starting a Phase 2 study of TNX-102 SL for Long Covid and reporting topline data from the ongoing first-in-human study of TNX-2100, a diagnostic skin test for T cell immunity to SARS-CoV-2, in the first half of 2022.”

Gregory Sullivan, M.D., Chief Medical Officer of Tonix said, “In 2022, we expect to initiate several clinical trials. We intend to start a Phase 1 study of TNX-1500, a humanized monoclonal antibody with several potential indications including the prevention of organ transplant rejection and treatment of autoimmune disorders. Within our CNS pipeline, we expect to start a Phase 2 study of FDA Breakthrough Therapy-designated product candidate TNX-1300 (recombinant cocaine esterase) for cocaine intoxication in the emergency room setting. We also expect to start three trials for TNX-102 SL (sublingual cyclobenzaprine) including: a confirmatory Phase 3 study for the management of fibromyalgia, a Phase 2 study for the treatment of PTSD, and a Phase 2 study for the treatment of Long Covid. Finally, in 2022 we intend to start a Phase 2 study of TNX-1900 for the treatment of migraine and an investigator-initiated Phase 2 study of TNX-1900 for binge eating disorder.”

Recent Highlights—Key Product Candidates*

Immunology Pipeline

TNX-1500 (anti-CD40L monoclonal antibody): third generation monoclonal antibody for prophylaxis of organ transplant rejection and treating autoimmune disorders.

  • Tonix expects to start a Phase 1 study in the second half of 2022. Preliminary results from ongoing experiments in heart and kidney transplants in non-human primates at Massachusetts General Hospital indicate that TNX-1500 appears to have monotherapy efficacy in promoting rejection-free transplant organ acceptance and no evidence of thrombosis has been observed.

TNX-1700 (stabilized recombinant trefoil factor 2, or rTFF2): biologic for gastric and colorectal cancers

  • In December 2021, Tonix announced a research collaboration with Columbia University focused on advancing TNX-1700 in the treatment of gastric and colorectal cancers. Tonix optioned worldwide rights to develop and commercialize products related to Columbia’s rTFF2 technology, and key patent claims have recently been issued in the U.S. The new project, “Development of rTFF2-Based Therapy to Enhance Immuno-Oncology Treatments,” is the first sponsored research project of this collaboration. The agreement with Columbia University gives Tonix the option to exclusively license new therapeutic candidates and other technologies that arise from the research collaboration for further development. TNX-1700 is in the preclinical stage of development.

Central Nervous System (CNS) Pipeline

TNX-1300 (recombinant double mutant cocaine esterase): biologic for life-threatening cocaine intoxication

  • Tonix expects to initiate a Phase 2 open-label safety study of TNX-1300 in an emergency room setting in the first half of 2022. TNX-1300 was licensed from Columbia University and a positive Phase 2a study of volunteer cocaine users in a controlled laboratory setting has been completed. TNX-1300 has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

TNX-102 SL (cyclobenzaprine HCl sublingual tablets): small molecule for the management of fibromyalgia (FM)

  • Tonix expects to report topline data from its second Phase 3 study, RALLY, in the first quarter of 2022. Tonix reported interim analysis of RALLY in July 2021 in which the independent data monitoring committee recommended stopping the study for futility. The Company therefore stopped enrollment of new participants while continuing those participating at that time to completion. Tonix plans to employ pharmacogenomic (PGx) techniques to compare the RALLY and RELIEF study populations, which may provide a path to precision medicine-based companion diagnostics for TNX-102 SL in FM.

  • Tonix expects to initiate a new Phase 3 study of TNX-102 SL in FM in the first half of 2022. The Company will use the results of RALLY, including the PGx data, to potentially improve the design of this study.

  • Tonix reported positive results from the Phase 3 RELIEF study for the management of fibromyalgia in December 2020.

TNX-102 SL for the treatment of Posttraumatic Stress Disorder (PTSD)

  • Tonix has completed a meeting with the FDA to discuss potential new endpoints for the treatment of PTSD and expects to begin enrolling a Phase 2 study of TNX-102 SL in police in Kenya in the first half of 2022. The new PTSD study will use one month look-back CAPS-5 as the primary endpoint rather than one week look-back.

TNX-102 SL for the treatment of Long Covid, also known as Post-Acute Sequelae of COVID-19 (PASC)

  • The Company intends to initiate a Phase 2 study in patients with Long Covid in the first half of 2022, pending clearance of an Investigational New Drug (IND) application. The Phase 2 study will focus on a subset of Long Covid patients whose symptoms overlap with those of fibromyalgia.

TNX-1900 (intranasal potentiated oxytocin): small peptide for migraine, craniofacial pain, insulin resistance and related disorders, and binge eating disorder

  • In November 2021, Tonix announced it received IND clearance from the FDA to support the initiation of a Phase 2 study of TNX-1900 for the prevention of migraine headache in chronic migraineurs. The 505(b)(2) pathway for FDA approval is expected to be acceptable for this program, which is available to new formulations of an approved drug. The Company expects to begin enrollment in the second half of 2022.

  • In March 2022, Tonix announced an agreement with Massachusetts General Hospital to evaluate TNX-1900 in an investigator-initiated Phase 2 clinical trial as a potential treatment for patients with binge eating disorder. The Phase 2 clinical trial is expected to start in the second half of 2022.

  • Tonix’s potentiated formulation includes magnesium (Mg), which has been reported to potentiate the binding of oxytocin to the oxytocin receptor. Further evidence for the role of Mg in potentiating the effects of oxytocin at the oxytocin receptor were published by a third party1.

TNX-2900 (intranasal potentiated oxytocin): small peptide for the treatment of Prader-Willi syndrome (PWS)

  • In March 2022, the FDA granted the Company Orphan-Drug designation for TNX-2900 for the treatment of PWS.
  • In February 2022, Tonix entered into a sponsored research agreement with Inserm (the French National Institute of Health and Medical Research) and Aix-Marseille Université to study oxytocin in the genetically engineered mouse model of Prader-Willi syndrome, a rare genetic disorder that causes distinct, but related pathological eating disorders in adults and newborns. In adults, PWS causes hyperphagia, or pathological over-eating, which leads to obesity and other complications associated with significant mortality. In newborns, PWS causes a deficiency in suckling, which can lead to low muscle tone and failure to thrive, and has been shown to be normalized by oxytocin treatment.

TNX-601 CR (tianeptine oxalate and naloxone controlled-release tablets): small molecule for the treatment of major depressive disorder, PTSD and neurocognitive dysfunction associated with corticosteroid use.

  • Based on official minutes from a pre-IND meeting with the FDA, the Company expects to initiate a Phase 2 study for the treatment of major depressive disorder (depression) in the first quarter of 2023. Tonix plans to initiate a pharmacokinetic study in the third quarter of 2022. Tonix previously completed a Phase 1 trial for formulation development outside of the U.S.

Infectious Disease Pipeline

TNX-801 (live horsepox virus vaccine for percutaneous administration): smallpox and monkeypox vaccine designed as a single-administration vaccine to elicit T cell immunity

  • Tonix previously reported protection of non-human primates from a monkeypox challenge2. TNX-801 is less virulent than traditional vaccinia vaccines in mice.3

TNX-1840 /-1850 (live virus vaccines based on Tonix’s recombinant pox virus vector): COVID-19 vaccines designed as a single-administration vaccine to elicit T cell immunity

  • Because the omicron variant has out-competed the ancestral Wuhan strain, Tonix is now planning new versions of the TNX-1800 vaccine: TNX-1840 and TNX-1850, that are designed to express spike protein from the omicron and BA.2 variants, respectively. TNX-1840 and TNX-1850 are next-generation COVID-19 vaccines using live virus technology, which is known to primarily elicit a T cell response believed to result in longer durability and the blocking of forward transmission.

TNX-3500 (sangivamycin): antiviral inhibitor of SARS-CoV-2 for the treatment of COVID-19 and potential other viral disorders

  • In November 2021, Tonix announced the publication of “Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties,” in JCI Insight. The paper includes in vitro studies conducted by the National Institutes of Allergy and Infectious Diseases that show sangivamycin, the active pharmaceutical ingredient in TNX-3500, is a potent antiviral against SARS-CoV-2, the cause of COVID-19, and suppresses viral replication in tissue culture with greater potency than remdesivir, the active pharmaceutical ingredient of Gilead Sciences, Inc.’s Veklury®. When tested in combination with remdesivir, both drugs had additive rather than competitive effect against SARS-CoV-2.

  • Tonix plans to conduct further nonclinical animal studies of TNX-3500.

TNX-3600: COVID-19 therapeutic; fully human monoclonal antibody platform

  • In September 2021, Tonix expanded its research collaboration with Columbia University focused on studying immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic, as well as studying in vitro T cell and antibody responses to SARS-CoV-2, the virus that causes COVID-19. The research is designed to fill in important gaps in comprehensive understanding of immune responses to COVID-19, and to provide a foundation for tailoring vaccines and therapeutics to appropriate individuals with precision medicine. Specifically, the researchers will study T cell and antibody responses in a variety of ways, including at the cellular level by stimulating T cells in vitro with CoV-2 antigens and by generating fully human monoclonal antibodies against SARS-CoV-2. Tonix believes that this research has the potential to lead to the isolation, characterization and cloning of therapeutically relevant fully human neutralizing monoclonal antibodies to SARS-CoV-2.

TNX-3700: COVID-19 mRNA vaccine candidate using a zinc nanoparticle (ZNP) formulation

  • In January 2022, Tonix announced an exclusive option and research collaboration with Kansas State University (K-State) to develop ZNP mRNA vaccines that replace the lipid nanoparticle (LNP) technology in current COVID-19 vaccines. The new ZNP technology has the potential to confer increased stability to mRNA vaccines over a wide range of temperatures, addressing limits to rapid global deployment. Under the research agreement, K-State will advance preclinical development of a new ZNP mRNA vaccine to protect against COVID-19 based on the spike protein from SARS-CoV-2.

TNX-2100 (diagnostic skin test): SARS-CoV-2 epitope peptide mixtures for intradermal administration to measure the delayed-type hypersensitivity (DTH) reaction to SARS-CoV-2

  • Tonix initiated enrollment in a first-in-human, dose-finding clinical study for TNX-2100, which is designed to measure functional in vivo T cell immunity to SARS-CoV-2, with results expected in the first half of 2022.
  • TNX-2100 comprises three different mixtures of synthetic peptides (TNX-2110, -2120 and -2130), which has the potential to serve as: 1) a biomarker for T cell protective immunity and durability of vaccine protection; 2) a personalized approach for vaccine boosters; 3) a method to stratify participants in COVID-19 vaccine trials with a more complete picture of immune status; 4) an endpoint in COVID-19 vaccine trials for vaccines that elicit T cell immunity, and 5) public health surveillance.

*All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.

2021 Highlights—Facilities and Corporate

  • In December 2021, Tonix was added to the Nasdaq Biotechnology Index as part of Nasdaq’s annual reconstitution process.

  • In June 2021, Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes.

  • R&D Center (RDC): In October 2021, Tonix completed the acquisition of its 48,000 square foot research and development center (RDC) in Frederick, Md. The facility is operational and will focus on the development of vaccines and antiviral drugs against COVID-19, its variants, and other infectious diseases. The RDC facility is currently biosafety level 2 (BSL-2), but Tonix plans to make appropriate upgrades and seek certification for BSL-3 so that research may be conducted on live SARS-CoV-2 and other pathogens.

  • Advanced Development Center (ADC): In August 2021, Tonix commenced construction on the ADC for the development and manufacturing of Good Manufacturing Practice, or GMP, live-virus vaccines to support Phase 1 and 2 clinical trials. The facility, located in the New Bedford Business Park in Dartmouth, Mass., is planned to be BSL-2 and expected to be partially operational in the first half of 2022.

  • Commercial Manufacturing Center (CMC): Tonix plans to build the CMC in Hamilton, Mont. where it purchased approximately 44 acres of land. The CMC will focus on developing and manufacturing commercial scale live-virus vaccines and is also intended to be BSL-2. Site enabling work is expected to be initiated for the CMC in 2022.

1Meyerowitz, J.G., Robertson, M.J., Barros-Álvarez, X. et al. The oxytocin signaling complex reveals a molecular switch for cation dependence. Nat Struct Mol Biol (2022). https://doi.org/10.1038/s41594-022-00728-4
2Noyce, RS, et al. Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Presented as a poster at the American Society of Microbiology BioThreats Conference – January 29, 2020, Arlington, VA. (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf )
3Noyce RS, et al. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS One. 2018 Jan 19;13(1): e0188453.

Recent Highlights–Financial

As of December 30, 2021, Tonix had $178.7 million of cash and cash equivalents, compared to $77.1 million as of December 31, 2020. Subsequent to December 31, 2021, the Company sold 15.6 million shares of common stock in at-the-market offerings (ATM) sales under a Sales Agreement with A.G.P./Alliance Global Partners, for net proceeds of approximately $4.3 million. Additionally, the Company sold 22.0 million shares of common stock under the Purchase Agreement with Lincoln Park for net proceeds of approximately $4.5 million.

Cash used in operations was approximately $75.6 million for the full year ended December 31, 2021, compared to $48.6 million for the full year ended December 31, 2020. The increase in primarily due to an increase in research and development (R&D) and general and administrative (G&A) activities, described below.

Fourth Quarter 2021 Financial Results

R&D expenses for the fourth quarter of 2021 were $22.3 million, compared to $12.1 million for the same period in 2020. This increase is predominately due to increased clinical expenses of $1.9 million, increased manufacturing expenses of $2.1 million, non-clinical expenses of $2.4 million, employee-related expenses of $2.3 million and regulatory/legal expenses of $0.6 million. We expect R&D expenses to increase during 2022 as we move our clinical development programs forward and continue to invest in our development pipeline.

G&A expenses for the fourth quarter of 2021 were $7.3 million, compared to $4.9 million for the same period in 2020. The increase is primarily due to employee-related expenses of $1.8 million.

Net loss available to common stockholders was $29.6 million, or $0.07 per share, basic and diluted, for the fourth quarter of 2021, compared to net loss of $17.0 million, or $0.10 per share, basic and diluted, for the fourth quarter of 2020. The basic and diluted weighted average common shares outstanding for the fourth quarter of 2021 was 451,209,777, compared to 163,873,489 shares for the fourth quarter of 2020.

Full Year 2021 Financial Results

R&D expenses for full year 2021 were $68.8 million, compared to $36.2 million for the same period in 2020. This increase is predominately due to increased non-clinical expenses of $14.0 million, manufacturing expenses of $10.9 million, employee-related expenses of $5.3 million and regulatory/legal expenses of $1.9 million. We expect R&D expenses to increase during 2022 as we move our clinical development programs forward and continue to invest in our development pipeline.

G&A expenses for full year 2021 were $23.5 million, compared to $14.4 million for the same period in 2020. The increase is primarily due to employee-related expenses of $4.9 million, an increase in legal fees of $0.7 million due to increased patent prosecution costs, an increase in investor relations/public relations expenses of $0.6 million, an increase in financial reporting expenses of $1.2 million, and an increase in insurance premiums of $0.4 million.

Net loss available to common stockholders was $92.3 million, or $0.26 per share, basic and diluted, for full year 2021, compared to net loss of $52.2 million, or $0.55 per share, basic and diluted, for full year 2020. The basic and diluted weighted average common shares outstanding for full year 2021 was 360,215,323, compared to 94,591,715 shares for full year 2020.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, central nervous system (CNS) and infectious disease product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including Tonix’s lead immunology candidate, TNX-15001, is a humanized monoclonal antibody targeting CD40 ligand being developed for the prevention of allograft rejection and the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to start in the second half of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL2, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug in mid-Phase 3 development for the management of fibromyalgia, with a new Phase 3 study expected to start in the first half of 2022. TNX-102 SL is also being developed to treat Long COVID, a chronic post-COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the first half of 2022. TNX-13003 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the first half of 2022. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox, next-generation vaccines to prevent COVID-19 and an antiviral to treat COVID-19. Tonix’s lead vaccine program is TNX-801 (live horsepox virus for percutaneous administration) for preventing smallpox and monkeypox4. Horsepox is also the basis for Tonix’s recombinant pox vaccine (RPV) platform. Tonix’s lead vaccine candidates for COVID-19, TNX-1840 and TNX-18505, are live virus vaccines in development based on the RPV platform. Finally, TNX-35006 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development.

1TNX-1500 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

2TNX-102 SL is an investigational new drug and has not been approved for any indication.

3TNX-1300 is an investigational new biologic and has not been approved for any indication.

4TNX-801 is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.

5TNX-1840 and TNX-1850 are investigational new biologics at the pre-IND stage of development and have not been approved for any indication. TNX-1840 and TNX-1850 are designed to express the spike protein of SARS-CoV-2 from omicron and BA.2 variants, respectively, based on the experience from TNX-1800, which expresses the spike protein from the ancestral Wuhan strain.

6TNX-3500 is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K and periodic reports filed with the SEC. All Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

TONIX PHARMACEUTICALS HOLDING CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, In Thousands, Except Share and Per Share Amounts)

      Full Year Ended       Three Months Ended   
      December 31,         December 31,    
      2021       2020       2021       2020  
Costs and expenses                                
Research and development   $ 68,838     $ 36,157     $ 22,296     $ 12,097  
General and administrative     23,474       14,354       7,264       4,926  
Total costs and expenses     92,312       50,511       29,560       17,023  
Operating loss     (92,312 )     (50,511 )     (29,560 )     (17,023 )
Interest income, net     25       48       7       2  
Net loss   $ (92,287 )   $ (50,463 )   $ (29,553 )   $ (17,021 )
Warrant deemed dividend           (451 )            
Preferred stock deemed dividend           (1,260 )            
Net loss available to common stockholders   $ (92,287 )   $ (52,174 )   $ (29,553 )   $ (17,021 )
Net loss per common share, basic and diluted   $ (0.26 )   $ (0.55 )   $ (0.07 )   $ (0.10 )
Weighted average common shares outstanding, basic and diluted     360,215,323       94,591,715       451,209,777       163,873,489  


     

TONIX PHARMACEUTICALS HOLDING CORP.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2021 AND 2020
(In Thousands)

  December 31, 20211
  December 31, 20201
Assets    
Cash and cash equivalents $ 178,660   $ 77,068
Prepaid expenses and other   10,389     10,921
Total current assets   189,049     87,989
Other non-current assets   51 ,851     10,194
Total assets $ 240,900   $ 98,183
     
Liabilities and stockholders’ equity    
Total liabilities $ 22,183   $ 10,535
Stockholders’ equity   218,717     87,648
Total liabilities and stockholders’ equity $ 240,900   $ 98,183

The condensed consolidated balance sheets for the years ended December 31, 2021 and December 31, 2020 have been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505

Source: Tonix Pharmaceuticals Holding Corp.

New York Marijuana Seeding Opportunity Initiative is One-of-a-kind


Image: Jurassic Blueberries (Flickr)


NYS Office of Cannabis Management Experiments With Synergistic Effects of Marijuana and Social Equity

 

The first marijuana dispensary and farm licenses in New York State will be managed to help provide reparations for those that have been previously convicted of pot-related crimes.  Details of the plan were just provided by the Governor’s Press Office and are designed to provide a pathway for cannabis business ownership to benefit those who have been directly impacted by prior convictions.

New York approved the legalization of recreational marijuana on March 31, 2021.

Farm to Store “Seeding Opportunity”

New York’s Governor Kathy Hochul announced the novel Seeding Opportunity Initiative, which positions individuals with prior cannabis-related criminal offenses to be the first adult-use cannabis sales with products grown by New York farmers. The farm-to-store design is expected to allow the first legal recreational sales under the law before year-end 2022. The intent of the initiative is it “jumpstarts, New York’s cannabis industry, guarantees support for future equity applicants, and secures an early investment into communities most impacted by the disproportionate enforcement of cannabis prohibition.”

“New York State is making history, launching a first-of-its-kind approach to the cannabis industry that takes a major step forward in righting the wrongs of the past,” Governor Hochul said. “The regulations advanced by the Cannabis Control Board today will prioritize local farmers and entrepreneurs, creating jobs and opportunity for communities that have been left out and left behind. I’m proud New York will be a national model for the safe, equitable, and inclusive industry we are now building,” said Hochul.

“Social Equity”

The opening date of the application portal for both farms and dispensaries is March 15.  It is expected that the process will allow planting during the Spring. 

New York’s Office of Cannabis Management (OCM) Executive Director Chris Alexander said, “With the Seeding Opportunity Initiative, we are now on the path to doing what no state has done before: Put our farmers and equity entrepreneurs, not big, out of state businesses, at the forefront of the launch of our adult-use cannabis market. Thanks to the support of Governor Hochul and the action taken by the Board today, we’ve made a huge advancement in our efforts to prioritize New York’s small farmers, our equity entrepreneurs, and ultimately our goal to generate the resources that will support future equity applicants and drive investments into our communities most impacted by cannabis prohibition. We aren’t stopping here and work is already underway across all license types to open access to capital and develop supporting networks to build an equitable New York Cannabis Industry and setup our small businesses for long-term success.”

The plan weaves a number of the Governor’s priorities together to help serve the state’s objectives. Aside from leveling the playing field for New York residents with prior marijuana convictions, the MRTA will also “prioritize and provide resources” to other groups that face barriers to entry into the state’s new cannabis industry. According to a fact sheet provided with the release, these include minority and women-owned businesses, distressed farmers and service-disabled veterans who will be encouraged to participate. The cannabis management fact sheet also says it will give preference to those applicants earning below 80% of the national average.

Take-Away

New York expects the first dispensary licenses within the state to go to NYS residents that have been convicted of marijuana crime(s). Farmers with similar convictions will also be given priority status. The “social equity” portion of the implementation also includes preference to those making below a certain amount, and women and minority-owned businesses.

New York hopes to develop an ecosystem where what is sold locally for recreational use, is sown locally.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Cannabis Legalization and the Road for Psychedelics



Acceptance of Psychedelics for Wellness and Recreation





Cannabis Store Openings in Canada Only Slightly Affected the Number of Users



Does Net Profit Matter for Marijuana Stocks?

 

Sources

http://smart-ny.com/wp-content/uploads/2017/06/MRTA-Bill-Summary_04.8.2019.pdf

https://www.governor.ny.gov/news/governor-hochul-signs-conditional-cannabis-cultivation-bill

https://cannabis.ny.gov/adult-use


 

Stay up to date. Follow us:

 

A Global Reimagined Health Ecosystem




Life Sciences Supermind Report outlines proposed solutions to re-imagine the global health ecosystem

 

MIT Center for Collective Intelligence | MIT
Media Lab

 

The Covid-19 pandemic sent shockwaves through the life science ecosystem, uniting the scientific community with a common purpose and re-imagining pathways to address global health challenges.

To help accelerate that innovation, the MIT Center for Collective Intelligence, the MIT Media Lab’s Community Biotechnology Initiative, and MilliporeSigma — the U.S. and Canadian life science business of Merck KGaA, Darmstadt, Germany — together convened more than 200 thought leaders from around the world to collaboratively capture the disruptions caused by the pandemic and identify the solutions that will help usher in the future of the life sciences.

A comprehensive
report
containing synthesized, data-driven insights from this expert group, known as the “Life Sciences Supermind,” has now been published. The work builds on the collaborators’ research from 2020, which focused on pandemic response efforts, to outline the most promising solutions to build health resilience for now and the future.

The Life Sciences Supermind Report represents 18 months of global collaboration and expert synthesis, applying an accelerated methodology to identify solutions amid the urgency of a pandemic. During the invite-only curation exercise that ran for four weeks in May 2021, the Supermind convened using the Center for Collective Intelligence’s software platform and methodology to address a central challenge question: How do we identify and apply the lessons learned from the Covid-19 pandemic to re-imagine the institutions, processes, policies and tools we use across the life sciences to address global health needs for all?

David Sun Kong, director of the Community Biotechnology Initiative within the MIT Media Lab and author of the report, says, “Building upon last year’s effort, we widened the scope of our exploration to think deeply about the future of the entire life sciences ecosystem. In the coming years, human civilization faces unprecedented challenges that will require the global life sciences community to innovate, coordinate, and act. We believe many of the ideas and strategies presented in this report can help guide our future directions.”

During this sprint, the Supermind identified gaps and innovative solutions across five key technical areas, including the future of scientific research; public health preparedness, science and technologies; science communication; disruptive technologies; and flexible and resilient manufacturing, supply, and distribution chains. Synthesizing the results of this exercise, the Supermind Report was published in thematic installments from June to November 2021 and is now released in full for the first time.

“Typically, Supermind participants contribute ideas to the platform asynchronously throughout the multi-week exercise. This year, we added a new activity to our methodology where Supermind participants collaborated during online video sessions to develop solutions together,” says Kathleen Kennedy, executive director of the Center for Collective Intelligence, who oversaw the Supermind platform. “The combination of synchronous and asynchronous collaboration proved to be a powerful combination.”

The Supermind provided an early signal on new modes of global collaboration that have the potential to build public health resilience for all. Experts identified innovative ideas such as creating a new field of public health technology to unite technology leadership and expertise with the design of public health programs, products and initiatives. This strategy has since been leveraged more broadly in the fight against Covid-19, sparking innovative partnerships between technology, design, medical, and public health professionals to respond to this global health emergency.

The Supermind Report also details key findings on building diverse and open communities to accelerate scientific discovery; deploying novel, open-source technologies for diagnostics and transmission control; combating the “infodemic” through integrated disciplines that tackle information overload; and restructuring talent development in the life sciences, among other innovative strategies identified throughout the exercise.

The initiative’s unique methodology applied natural language processing to cluster and synthesize contributions from the participants. Participants contributed to the online platform asynchronously with daily facilitation. In total, 137 individual ideas were put forward during the 2021 exercise, garnering more than 700 votes cast for the top solutions during an evaluation phase. These were then supplemented by synchronous deliberation geared toward identifying more specific pathways to implementation and actionable outcomes.

“By bringing together a diverse group of experts, we were able to leverage their collective knowledge and compile the findings,” says Patrick Schneider, head of strategy, business development, and innovation for the Research Solutions business unit at MilliporeSigma and chair of the Life Science Innovation Board. “The result is a report that highlights novel ideas that have the ability to impact the future of life sciences. I look forward to taking these ideas and putting them into action.”

The Life Sciences Supermind demonstrates the power of collective intelligence in identifying the most feasible, impactful solutions to re-imagine the global health ecosystem and build health resilience for now and in the future. Looking to a post-pandemic world, these lessons, strengths, and accelerated pathways to solutions have the power to usher in a paradigm shift across scientific and global health industries.

 

Suggested Content



Baudax Bio C-Suite Interview (Video)



Axcella Therapeutics C-Suite Interview (Video)





Cocrystal Pharma Inc. Virtual Roadshow (Video)



Flotek Industries Interview (Video)

 

Stay up to date. Follow us:

 

Lineage Cell Therapeutics (LCTX) – FY2021 Reported With Updates For Pipeline Development

Friday, March 11, 2022

Lineage Cell Therapeutics (LCTX)
FY2021 Reported With Updates For Pipeline Development

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Full Year Financials In Line With Expectations.  Lineage Cell reported a 4Q21 loss of $28.2 million or $(0.17) per share, and a loss of $43.0 million or $(0.26) per share for FY21. The larger than expected loss in 4Q21 was due to the accrual of $20.6 million for future obligations payable to its licensors under the December 2021 Genentech/Roche Agreement. The company ended the year with $55.7 million in cash, excluding proceeds from the Genentech agreement.

    Genentech/Roche Agreement Transformed The Company.  In December 2021, Lineage Cell made a collaboration and licensing agreement covering OpRegen, its retinal pigmented epithelial cell transplant for ophthalmologic indications. Genentech/Roche will take over the clinical development and commercialization, in exchange for $50 million in upfront fees, $620 million in potential milestone payments, then …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Item 9 Labs (INLB) – Begins Capital Raise Closes on First Dispensary Acquisition

Thursday, March 10, 2022

Item 9 Labs (INLB)
Begins Capital Raise; Closes on First Dispensary Acquisition

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Capital Raise. Yesterday, Item 9 Labs announced the launch of its global, streamlined Regulation A, Tier 2 public offering for unaccredited and accredited investors. The Company is offering 28 million units, each comprised of one share and one-half of one warrant. Upon the exercise of all warrants, the offering has maximum proceeds of $67.2 million. The offering price is $1.40 per unit and the exercise price is $2.00 per warrant share.

    To Fuel Growth.  The net proceeds of the offering will be used to fuel growth. Proceeds will be used to fund the Company’s retail dispensary acquisition strategy, for the potential acquisition of additional cultivation properties, and for working capital purposes. Assuming funds are raised, we believe this would be a net positive for Item 9 Labs as the additional capital would enable an acceleration …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with CC-42344



Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

Research, News, and Market Data on Cocrystal Pharma

 

BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered antiviral CC-42344 for the treatment of pandemic and seasonal influenza A. The study is designed to assess the safety, tolerability and pharmacokinetics of CC-42344 with results expected later this year.

The randomized, double-blind, placebo-controlled Phase 1 study is expected to enroll up to 56 healthy adults at a single site in Australia. CC-42344 is an oral PB2 inhibitor that blocks an essential step of influenza viral replication and transcription. CC-42344 was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology.

“There is an urgent need for new antiviral medicines that address pandemic and drug-resistant seasonal influenza strains,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “CC-42344 specifically targets the PB2 protein of influenza polymerase complex and exhibits broad-spectrum antiviral activity including against Tamiflu- or Xofluza-resistant strains. In preclinical testing, CC-42344 has shown favorable pharmacokinetic and safety profiles. Advancing CC-42344 into clinical studies further validates our proprietary drug discovery platform technology.”

“Enrolling the first participants represents a significant milestone in advancing the development of CC-42344 for the treatment of this highly contagious viral infection that can have life-threatening complications,” added James Martin, Cocrystal’s CFO and co-interim CEO. “This study is the first of three first-in-human trials we expect to initiate in 2022, with the other two evaluating our novel antiviral therapeutic candidates for SARS-CoV-2.”

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our planned initiation of influenza A Phase 1 study in Australia in 2022 , and the potential of CC-42344 to treat seasonal and pandemic influenza The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from any future impact of the COVID-19 pandemic and the Russian invasion of Ukraine on the Australian and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Media Contact:
JQA Partners
917-885-7378
Jabraham@jqapartners.com

Source: Cocrystal Pharma, Inc.

Release – TherapeuticsMD Announces Fourth Quarter 2021 Financial Results



TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Research, News, and Market Data on TherapeuticsMD

 

– Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women’s healthcare –
– Amended credit terms with 
Sixth Street in support of a new capitalization plan –
– Conference call scheduled for 
8:30 a.m. ET today –

BOCA RATON, Fla.–(BUSINESS WIRE)–Mar. 10, 2022– 
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the fourth quarter ended 
December 31, 2021.

“We spent the past three months executing on four key priorities set forth last quarter, and today we announced that we have accomplished two of them. With the definitive agreement to fully divest our vitaCare business unit, TXMD will emerge as a more focused company aimed at empowering women of all ages through better and affordable healthcare. Amending our credit terms is, in our view, the most prudent way to achieve the necessary financial flexibility to complete the announced sale of vitaCare and ultimately refinance our existing credit facility,” said Hugh O’Dowd, CEO of 
TherapeuticsMD.

“Demand for our flagship product, ANNOVERA®, continues to grow. We are working to ensure ample supply and drive towards uninterrupted access to this important contraceptive. We are excited about our future, and believe we are on a pathway towards serving women as they navigate their healthcare needs,” concluded O’Dowd.

Fourth Quarter 2021 Financial Results and Business Highlights

Three Months ended
December 31,

2021

 

2020

Product revenue:
ANNOVERA

$ 7,831

$ 9,084

IMVEXXY

6,667

8,820

BIJUVA

2,680

2,244

Prescription vitamin

1,500

2,430

Product revenue, net

18,678

22,578

License revenue

Total revenue, net

$ 18,678

$ 22,578

ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

  • ANNOVERA net product revenue of 
    $7.8 million for the fourth quarter of 2021 decreased by 
    $1.3 million compared to 
    $9.1 million for the fourth quarter of 2020.
  • Approximately 9,315 ANNOVERA prescriptions were dispensed to patients during the fourth quarter of 2021, an increase of 11% from the third quarter of 2021, and 57% from the fourth quarter of 2020.
  • Over 10,750 healthcare providers (HCPs) prescribed ANNOVERA during the fourth quarter, of which nearly 1,300 were new writers.
    • Growth in prescribers of approximately 119% over fourth quarter of 2020.

IMVEXXY® (estradiol vaginal inserts)

  • IMVEXXY net product revenue of 
    $6.7 million for the fourth quarter of 2021 decreased by 
    $2.2 million compared to 
    $8.8 million for the fourth quarter of 2020.
  • Approximately 109,300 IMVEXXY prescriptions were dispensed to patients during the fourth quarter of 2021.

BIJUVA® (estradiol and progesterone) capsules

  • BIJUVA net product revenue of 
    $2.7 million for the fourth quarter of 2021 increased by 
    $0.4 million compared to 
    $2.2 million for the fourth quarter of 2020.
  • BIJUVA net product revenue for the fourth quarter of 2021 includes 
    $0.7 million of export sales through our international licensing and supply agreement with 
    Theramex HQ UK Limited.

Cost of Goods Sold and Gross Margin

  • Cost of goods was 
    $4.7 million with product gross margin of 75% for the fourth quarter of 2022 compared to 
    $5.6 million with product gross margin of 75% for the fourth quarter of 2020.

Operating Expense, Net Loss and Related Information

  • Total operating expense of 
    $49.3 million for the fourth quarter of 2021 decreased by 
    $2.3 million compared to 
    $51.6 million for the fourth quarter of 2020. Included in total operating expense for the fourth quarter of 2021 was 
    $5.1 million of severance related expenses recorded for a former executive. Without the executive severance, operating expense for the fourth quarter of 2021 would have been 
    $44.3 million, a decrease of 
    $7.3 million compared to the fourth quarter of 2020.
  • Net loss for the fourth quarter of 2021 was 
    $43.0 million, or 
    $0.10 per basic and diluted share, compared to net loss for the fourth quarter of 2020 of 
    $42.1 million, or 
    $0.15 per basic and diluted share. Without the executive severance, net loss for the fourth quarter of 2021 would have been 
    $37.9 million, or 
    $0.09 per basic and diluted share.

Balance Sheet

  • As of 
    December 31, 2021, the Company’s cash on hand totaled 
    $65.1 million, compared with 
    $80.5 million as of 
    December 31, 2020.
  • For 2021, the Company received 
    $184.1 million in net proceeds from its at-the-market and underwritten equity offerings.
  • As of 
    December 31, 2021, the remaining outstanding principal amount under the Company’s Financing Agreement was 
    $200.0 million, which reflects a repayment of 
    $50.0 million of principal during 2021.

Conference Call and Webcast Details

TherapeuticsMD will host a conference call and live audio webcast today at 
8:30 a.m. ET to discuss these financial results and provide a business update.

Date:

Thursday, March 10, 2022

Time:

8:30 a.m. ET

Telephone Access (US):

866-665-9531

Telephone Access (International):

724-987-6977

Access Code for All Callers:

6988467

A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the 
TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call’s completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 6988467.

Please see the Full Prescribing Information, including indication and Boxed WARNING, for each 
TherapeuticsMD product as follows:

Forward-Looking Statements

This press release by 
TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the 
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by such divestiture will be utilized; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility and the company’s ability to refinance such facility; the effects of supply chain issues on the supply of the company’s products; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the manufacturing supplement for ANNOVERA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the impact of leadership transitions; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

– Financial Statements to Follow –

TherapeuticsMD, Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands, except per share data)
 
 
As of 
December 31,

 

2021

 

 

 

2020

 

Assets:
Current assets:
Cash

$

65,122

 

$

80,486

 

Accounts receivable, net of allowance for credit losses of 
$1,334 and 
$1,118 as of

December 31, 2021 and 2020, respectively

 

36,176

 

 

32,382

 

Inventory

 

7,622

 

 

7,993

 

Prepaid and other current assets

 

10,548

 

 

7,543

 

Total current assets

 

119,468

 

 

128,404

 

Fixed assets, net

 

1,199

 

 

1,942

 

License rights and other intangible assets, net

 

40,318

 

 

41,445

 

Right of use assets

 

8,234

 

 

9,566

 

Other non-current assets

 

253

 

 

253

 

Total assets

$

169,472

 

$

181,610

 

Liabilities and stockholders’ equity (deficit):
Current liabilities:
Current maturities of long-term debt

$

188,269

 

$

 

Accounts payable

 

20,318

 

 

21,068

 

Accrued expenses and other current liabilities

 

44,304

 

 

38,170

 

Total current liabilities

 

252,891

 

 

59,238

 

Long-term debt, net

 

 

 

237,698

 

Operating lease liabilities

 

8,063

 

 

8,675

 

Other non-current liabilities

 

2,139

 

 

 

Total liabilities

 

263,093

 

 

305,611

 

Commitments and contingencies
Stockholders’ deficit:
Preferred stock, par value 
$0.001; 10,000 shares authorized, none issued

 

 

 

 

Common stock, par value 
$0.001; 600,000 shares authorized, 429,886 and 299,765
issued and outstanding as of 
December 31, 2021 and 2020, respectively

 

430

 

 

300

 

Additional paid-in capital

 

957,309

 

 

754,644

 

Accumulated deficit

 

(1,051,360

)

 

(878,945

)

Total stockholders’ deficit

 

(93,621

)

 

(124,001

)

Total liabilities and stockholders’ deficit

$

169,472

 

$

181,610

 

TherapeuticsMD, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited – in thousands, except per share data)
 
Three Months ended
December 31, Year ended 
December 31,

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

Revenue:
Product revenue, net

$

18,678

 

$

22,578

 

$

85,780

 

$

62,872

 

License revenue

 

 

 

 

 

1,171

 

 

2,000

 

Total revenue, net

 

18,678

 

 

22,578

 

 

86,951

 

 

64,872

 

Cost of goods sold

 

4,737

 

 

5,581

 

 

18,838

 

 

15,975

 

Gross profit

 

13,941

 

 

16,997

 

 

68,113

 

 

48,897

 

Operating expenses:
Selling and marketing

 

22,002

 

 

25,996

 

 

108,195

 

 

117,052

 

General and administrative

 

25,911

 

 

23,214

 

 

92,602

 

 

76,954

 

Research and development

 

1,420

 

 

2,394

 

 

7,086

 

 

10,432

 

Total operating expenses

 

49,333

 

 

51,604

 

 

207,883

 

 

204,438

 

Loss from operations

 

(35,392

)

 

(34,607

)

 

(139,770

)

 

(155,541

)

Other (expense) income:
Interest expense and other financing costs

 

(7,576

)

 

(7,612

)

 

(32,917

)

 

(28,581

)

Other income, net

 

8

 

 

132

 

 

272

 

 

598

 

Total other (expense), net

 

(7,568

)

 

(7,480

)

 

(32,645

)

 

(27,983

)

Loss before income taxes

 

(42,960

)

 

(42,087

)

 

(172,415

)

 

(183,524

)

Provision for income taxes

 

 

 

 

 

 

 

 

Net loss

$

(42,960

)

$

(42,087

)

$

(172,415

)

$

(183,524

)

Loss per common share, basic and diluted

$

(0.10

)

$

(0.15

)

$

(0.43

)

$

(0.67

)

Weighted average common shares, basic and diluted

 

427,314

 

 

286,607

 

 

397,992

 

 

275,649

 

TherapeuticsMD, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited – in thousands)
 
 
Year ended 
December 31,

 

2021

 

 

 

2020

 

Cash flows from operating activities:
Net loss

$

(172,415

)

$

(183,524

)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

 

4,093

 

 

4,067

 

Charges to provision for doubtful accounts

 

533

 

 

238

 

Inventory charge

 

1,082

 

 

7,205

 

Debt financing fees

 

5,689

 

 

2,532

 

Share-based compensation

 

18,125

 

 

10,679

 

Other

 

720

 

 

2,673

 

Changes in operating assets and liabilities:
Accounts receivable

 

(4,327

)

 

(8,224

)

Inventory

 

(711

)

 

(3,337

)

Prepaid and other current assets

 

(3,005

)

 

3,209

 

Accounts payable

 

(750

)

 

1,887

 

Accrued expenses and other current liabilities

 

6,134

 

 

2,904

 

Other non-current liabilities

 

2,139

 

 

220

 

Total adjustments

 

29,722

 

 

24,053

 

Net cash used in operating activities

 

(142,693

)

 

(159,471

)

Cash flows from investing activities:
Payment of patent related costs

 

(2,189

)

 

(1,391

)

Purchase of fixed assets

 

(34

)

 

(207

)

Net cash used in investing activities

 

(2,223

)

 

(1,598

)

Cash flows from financing activities:
Proceeds from sale of common stock, net of costs

 

184,115

 

 

31,703

 

Proceeds from exercise of options and warrants

 

322

 

 

272

 

Proceeds from sale of common stock related to employee stock purchase plan

 

233

 

 

 

Repayments of debt

 

(50,000

)

 

 

Borrowings of debt

 

 

 

50,000

 

Payment of debt financing fees

 

(5,118

)

 

(1,250

)

Net cash provided by financing activities

 

129,552

 

 

80,725

 

Net increase in cash

 

(15,364

)

 

(80,344

)

Cash, beginning of period

 

80,486

 

 

160,830

 

Cash, end of period

$

65,122

 

$

80,486

 

Supplemental disclosure of cash flow information:
Interest paid

$

25,068

 

$

25,849

 

Supplemental disclosure of noncash financing activities:
Warrants issued in relation to debt financing agreement

$

 

$

7,668

 

 

James D’Arecca
Chief Financial Officer
561-961-1900

Lisa M. Wilson

In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com

Source: 
TherapeuticsMD, Inc.

Release – Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Symrise



Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

Research, News, and Market Data on Ceapro

 

– Symrise to distribute and commercialize Ceapro’s high value active ingredients in the cosmetic market –

– Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market –

EDMONTON, Alberta, March 10, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.

Under the agreement, Symrise is guaranteed to purchase minimum annual volumes of Ceapro’s high value active ingredients. Financial terms of the agreement were not disclosed.

“Symrise has been and will continue to be a valued, committed partner and we are very pleased to have renewed this agreement with them. This agreement not only provides security for our ongoing cosmeceuticals base business but also is expected to enable us to accelerate the growth of that base business through the potential to expand the list of exclusive customers to Symrise. We are delighted for the vote of confidence towards our Company and especially for the recognition of the quality and uniqueness of Ceapro’s products,” said Gilles Gagnon, President and CEO of Ceapro. “We are confident that our partnership with Symrise, one of the most respected player in our industry, will continue to equally aid in the achievement of our common goals” he added.

“Ceapro and Symrise have a long-standing relationship in product development that has benefitted both companies over the years,” said Joern Andreas, President Cosmetic Ingredients Division, Symrise AG. “We see great value in this partnership and are very pleased to have secured this agreement, which will continue to pave the way for future developments that I believe will benefit both companies in creating value.”

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources.

Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

About Symrise
Symrise is a global supplier of fragrances, flavors, food, nutrition and cosmetic ingredients. Its clients include manufacturers of perfumes, cosmetics, food and beverages, pharmaceuticals and producers of nutritional supplements and pet food. Headquartered in Holzminden, Germany, the Group is represented by more than 100 locations in Europe, Africa, the Middle East, Asia, the United States and Latin America. www.symrise.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INVESTOR AND MEDIA CONTACT:
Jenene Thomas
Jenene Thomas Communications, LLC
T (US): 908-938-1475
E: jenene@jenenethomascommunications.com

Source: Ceapro Inc.

Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise



Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

Research, News, and Market Data on Ceapro

 

– Symrise to distribute and commercialize Ceapro’s high value active ingredients in the cosmetic market –

– Supply and distribution agreement provides Symrise with exclusivity for several major key international customers in the cosmetic market –

EDMONTON, Alberta, March 10, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of a long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.

Under the agreement, Symrise is guaranteed to purchase minimum annual volumes of Ceapro’s high value active ingredients. Financial terms of the agreement were not disclosed.

“Symrise has been and will continue to be a valued, committed partner and we are very pleased to have renewed this agreement with them. This agreement not only provides security for our ongoing cosmeceuticals base business but also is expected to enable us to accelerate the growth of that base business through the potential to expand the list of exclusive customers to Symrise. We are delighted for the vote of confidence towards our Company and especially for the recognition of the quality and uniqueness of Ceapro’s products,” said Gilles Gagnon, President and CEO of Ceapro. “We are confident that our partnership with Symrise, one of the most respected player in our industry, will continue to equally aid in the achievement of our common goals” he added.

“Ceapro and Symrise have a long-standing relationship in product development that has benefitted both companies over the years,” said Joern Andreas, President Cosmetic Ingredients Division, Symrise AG. “We see great value in this partnership and are very pleased to have secured this agreement, which will continue to pave the way for future developments that I believe will benefit both companies in creating value.”

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources.

Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

About Symrise
Symrise is a global supplier of fragrances, flavors, food, nutrition and cosmetic ingredients. Its clients include manufacturers of perfumes, cosmetics, food and beverages, pharmaceuticals and producers of nutritional supplements and pet food. Headquartered in Holzminden, Germany, the Group is represented by more than 100 locations in Europe, Africa, the Middle East, Asia, the United States and Latin America. www.symrise.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INVESTOR AND MEDIA CONTACT:
Jenene Thomas
Jenene Thomas Communications, LLC
T (US): 908-938-1475
E: jenene@jenenethomascommunications.com

Source: Ceapro Inc.

TherapeuticsMD Announces Fourth Quarter 2021 Financial Results



TherapeuticsMD Announces Fourth Quarter 2021 Financial Results

Research, News, and Market Data on TherapeuticsMD

 

– Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women’s healthcare –
– Amended credit terms with 
Sixth Street in support of a new capitalization plan –
– Conference call scheduled for 
8:30 a.m. ET today –

BOCA RATON, Fla.–(BUSINESS WIRE)–Mar. 10, 2022– 
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the fourth quarter ended 
December 31, 2021.

“We spent the past three months executing on four key priorities set forth last quarter, and today we announced that we have accomplished two of them. With the definitive agreement to fully divest our vitaCare business unit, TXMD will emerge as a more focused company aimed at empowering women of all ages through better and affordable healthcare. Amending our credit terms is, in our view, the most prudent way to achieve the necessary financial flexibility to complete the announced sale of vitaCare and ultimately refinance our existing credit facility,” said Hugh O’Dowd, CEO of 
TherapeuticsMD.

“Demand for our flagship product, ANNOVERA®, continues to grow. We are working to ensure ample supply and drive towards uninterrupted access to this important contraceptive. We are excited about our future, and believe we are on a pathway towards serving women as they navigate their healthcare needs,” concluded O’Dowd.

Fourth Quarter 2021 Financial Results and Business Highlights

Three Months ended
December 31,

2021

 

2020

Product revenue:
ANNOVERA

$ 7,831

$ 9,084

IMVEXXY

6,667

8,820

BIJUVA

2,680

2,244

Prescription vitamin

1,500

2,430

Product revenue, net

18,678

22,578

License revenue

Total revenue, net

$ 18,678

$ 22,578

ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system)

  • ANNOVERA net product revenue of 
    $7.8 million for the fourth quarter of 2021 decreased by 
    $1.3 million compared to 
    $9.1 million for the fourth quarter of 2020.
  • Approximately 9,315 ANNOVERA prescriptions were dispensed to patients during the fourth quarter of 2021, an increase of 11% from the third quarter of 2021, and 57% from the fourth quarter of 2020.
  • Over 10,750 healthcare providers (HCPs) prescribed ANNOVERA during the fourth quarter, of which nearly 1,300 were new writers.
    • Growth in prescribers of approximately 119% over fourth quarter of 2020.

IMVEXXY® (estradiol vaginal inserts)

  • IMVEXXY net product revenue of 
    $6.7 million for the fourth quarter of 2021 decreased by 
    $2.2 million compared to 
    $8.8 million for the fourth quarter of 2020.
  • Approximately 109,300 IMVEXXY prescriptions were dispensed to patients during the fourth quarter of 2021.

BIJUVA® (estradiol and progesterone) capsules

  • BIJUVA net product revenue of 
    $2.7 million for the fourth quarter of 2021 increased by 
    $0.4 million compared to 
    $2.2 million for the fourth quarter of 2020.
  • BIJUVA net product revenue for the fourth quarter of 2021 includes 
    $0.7 million of export sales through our international licensing and supply agreement with 
    Theramex HQ UK Limited.

Cost of Goods Sold and Gross Margin

  • Cost of goods was 
    $4.7 million with product gross margin of 75% for the fourth quarter of 2022 compared to 
    $5.6 million with product gross margin of 75% for the fourth quarter of 2020.

Operating Expense, Net Loss and Related Information

  • Total operating expense of 
    $49.3 million for the fourth quarter of 2021 decreased by 
    $2.3 million compared to 
    $51.6 million for the fourth quarter of 2020. Included in total operating expense for the fourth quarter of 2021 was 
    $5.1 million of severance related expenses recorded for a former executive. Without the executive severance, operating expense for the fourth quarter of 2021 would have been 
    $44.3 million, a decrease of 
    $7.3 million compared to the fourth quarter of 2020.
  • Net loss for the fourth quarter of 2021 was 
    $43.0 million, or 
    $0.10 per basic and diluted share, compared to net loss for the fourth quarter of 2020 of 
    $42.1 million, or 
    $0.15 per basic and diluted share. Without the executive severance, net loss for the fourth quarter of 2021 would have been 
    $37.9 million, or 
    $0.09 per basic and diluted share.

Balance Sheet

  • As of 
    December 31, 2021, the Company’s cash on hand totaled 
    $65.1 million, compared with 
    $80.5 million as of 
    December 31, 2020.
  • For 2021, the Company received 
    $184.1 million in net proceeds from its at-the-market and underwritten equity offerings.
  • As of 
    December 31, 2021, the remaining outstanding principal amount under the Company’s Financing Agreement was 
    $200.0 million, which reflects a repayment of 
    $50.0 million of principal during 2021.

Conference Call and Webcast Details

TherapeuticsMD will host a conference call and live audio webcast today at 
8:30 a.m. ET to discuss these financial results and provide a business update.

Date:

Thursday, March 10, 2022

Time:

8:30 a.m. ET

Telephone Access (US):

866-665-9531

Telephone Access (International):

724-987-6977

Access Code for All Callers:

6988467

A live webcast and audio archive for the event may be accessed on the home page or from the “Investors & Media” section of the 
TherapeuticsMD website at www.therapeuticsmd.com. Please connect to the website prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for at least 30 days. In addition, a digital recording of the conference call will be available for replay beginning two hours after the call’s completion and for at least 30 days with the dial-in 855-859-2056 or international 404-537-3406 and Conference ID: 6988467.

Please see the Full Prescribing Information, including indication and Boxed WARNING, for each 
TherapeuticsMD product as follows:

Forward-Looking Statements

This press release by 
TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the 
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the effects of the COVID-19 pandemic; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by such divestiture will be utilized; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility and the company’s ability to refinance such facility; the effects of supply chain issues on the supply of the company’s products; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; whether the FDA will approve the manufacturing supplement for ANNOVERA; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the impact of leadership transitions; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

– Financial Statements to Follow –

TherapeuticsMD, Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands, except per share data)
 
 
As of 
December 31,

 

2021

 

 

 

2020

 

Assets:
Current assets:
Cash

$

65,122

 

$

80,486

 

Accounts receivable, net of allowance for credit losses of 
$1,334 and 
$1,118 as of

December 31, 2021 and 2020, respectively

 

36,176

 

 

32,382

 

Inventory

 

7,622

 

 

7,993

 

Prepaid and other current assets

 

10,548

 

 

7,543

 

Total current assets

 

119,468

 

 

128,404

 

Fixed assets, net

 

1,199

 

 

1,942

 

License rights and other intangible assets, net

 

40,318

 

 

41,445

 

Right of use assets

 

8,234

 

 

9,566

 

Other non-current assets

 

253

 

 

253

 

Total assets

$

169,472

 

$

181,610

 

Liabilities and stockholders’ equity (deficit):
Current liabilities:
Current maturities of long-term debt

$

188,269

 

$

 

Accounts payable

 

20,318

 

 

21,068

 

Accrued expenses and other current liabilities

 

44,304

 

 

38,170

 

Total current liabilities

 

252,891

 

 

59,238

 

Long-term debt, net

 

 

 

237,698

 

Operating lease liabilities

 

8,063

 

 

8,675

 

Other non-current liabilities

 

2,139

 

 

 

Total liabilities

 

263,093

 

 

305,611

 

Commitments and contingencies
Stockholders’ deficit:
Preferred stock, par value 
$0.001; 10,000 shares authorized, none issued

 

 

 

 

Common stock, par value 
$0.001; 600,000 shares authorized, 429,886 and 299,765
issued and outstanding as of 
December 31, 2021 and 2020, respectively

 

430

 

 

300

 

Additional paid-in capital

 

957,309

 

 

754,644

 

Accumulated deficit

 

(1,051,360

)

 

(878,945

)

Total stockholders’ deficit

 

(93,621

)

 

(124,001

)

Total liabilities and stockholders’ deficit

$

169,472

 

$

181,610

 

TherapeuticsMD, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited – in thousands, except per share data)
 
Three Months ended
December 31, Year ended 
December 31,

 

2021

 

 

 

2020

 

 

 

2021

 

 

 

2020

 

Revenue:
Product revenue, net

$

18,678

 

$

22,578

 

$

85,780

 

$

62,872

 

License revenue

 

 

 

 

 

1,171

 

 

2,000

 

Total revenue, net

 

18,678

 

 

22,578

 

 

86,951

 

 

64,872

 

Cost of goods sold

 

4,737

 

 

5,581

 

 

18,838

 

 

15,975

 

Gross profit

 

13,941

 

 

16,997

 

 

68,113

 

 

48,897

 

Operating expenses:
Selling and marketing

 

22,002

 

 

25,996

 

 

108,195

 

 

117,052

 

General and administrative

 

25,911

 

 

23,214

 

 

92,602

 

 

76,954

 

Research and development

 

1,420

 

 

2,394

 

 

7,086

 

 

10,432

 

Total operating expenses

 

49,333

 

 

51,604

 

 

207,883

 

 

204,438

 

Loss from operations

 

(35,392

)

 

(34,607

)

 

(139,770

)

 

(155,541

)

Other (expense) income:
Interest expense and other financing costs

 

(7,576

)

 

(7,612

)

 

(32,917

)

 

(28,581

)

Other income, net

 

8

 

 

132

 

 

272

 

 

598

 

Total other (expense), net

 

(7,568

)

 

(7,480

)

 

(32,645

)

 

(27,983

)

Loss before income taxes

 

(42,960

)

 

(42,087

)

 

(172,415

)

 

(183,524

)

Provision for income taxes

 

 

 

 

 

 

 

 

Net loss

$

(42,960

)

$

(42,087

)

$

(172,415

)

$

(183,524

)

Loss per common share, basic and diluted

$

(0.10

)

$

(0.15

)

$

(0.43

)

$

(0.67

)

Weighted average common shares, basic and diluted

 

427,314

 

 

286,607

 

 

397,992

 

 

275,649

 

TherapeuticsMD, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited – in thousands)
 
 
Year ended 
December 31,

 

2021

 

 

 

2020

 

Cash flows from operating activities:
Net loss

$

(172,415

)

$

(183,524

)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

 

4,093

 

 

4,067

 

Charges to provision for doubtful accounts

 

533

 

 

238

 

Inventory charge

 

1,082

 

 

7,205

 

Debt financing fees

 

5,689

 

 

2,532

 

Share-based compensation

 

18,125

 

 

10,679

 

Other

 

720

 

 

2,673

 

Changes in operating assets and liabilities:
Accounts receivable

 

(4,327

)

 

(8,224

)

Inventory

 

(711

)

 

(3,337

)

Prepaid and other current assets

 

(3,005

)

 

3,209

 

Accounts payable

 

(750

)

 

1,887

 

Accrued expenses and other current liabilities

 

6,134

 

 

2,904

 

Other non-current liabilities

 

2,139

 

 

220

 

Total adjustments

 

29,722

 

 

24,053

 

Net cash used in operating activities

 

(142,693

)

 

(159,471

)

Cash flows from investing activities:
Payment of patent related costs

 

(2,189

)

 

(1,391

)

Purchase of fixed assets

 

(34

)

 

(207

)

Net cash used in investing activities

 

(2,223

)

 

(1,598

)

Cash flows from financing activities:
Proceeds from sale of common stock, net of costs

 

184,115

 

 

31,703

 

Proceeds from exercise of options and warrants

 

322

 

 

272

 

Proceeds from sale of common stock related to employee stock purchase plan

 

233

 

 

 

Repayments of debt

 

(50,000

)

 

 

Borrowings of debt

 

 

 

50,000

 

Payment of debt financing fees

 

(5,118

)

 

(1,250

)

Net cash provided by financing activities

 

129,552

 

 

80,725

 

Net increase in cash

 

(15,364

)

 

(80,344

)

Cash, beginning of period

 

80,486

 

 

160,830

 

Cash, end of period

$

65,122

 

$

80,486

 

Supplemental disclosure of cash flow information:
Interest paid

$

25,068

 

$

25,849

 

Supplemental disclosure of noncash financing activities:
Warrants issued in relation to debt financing agreement

$

 

$

7,668

 

 

James D’Arecca
Chief Financial Officer
561-961-1900

Lisa M. Wilson

In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com

Source: 
TherapeuticsMD, Inc.